article thumbnail

Understanding the role of recombinant insulin in cell culture systems: What the studies say 

Pharmaceutical Technology

Among several growth-promoting supplements added to the cell culture media formulations, insulin is one of the most common. Recombinant insulin is used as a supplement in the upstream manufacturing of a range of biologic drugs, including recombinant proteins, such as monoclonal antibodies, viral vectors, and viruses.

Insulin 130
article thumbnail

Cell culture Q&A: Solving biomanufacturing challenges with Recombinant Insulin supplementation

Pharmaceutical Technology

It is no exaggeration to say that the world changed in the early 80s when insulin was expressed synthetically in microorganisms for the first time. This breakthrough led to a recombinant (biosynthetic) and thereby safer therapy for diabetes than the animal-sourced insulin which had been used since 1922.

Insulin 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

The issues are holding up discussions between the agency and company about labeling and post-marketing requirements for teplizumab, and are concentrated around the pharmacokinetics data for the antibody, and whether it is comparable to the drug that its original developer Eli Lilly entered into clinical trials.

article thumbnail

Self-injecting pill could offer oral administration for monoclonal antibodies, insulin and other drugs

BioPharma Reporter

A new type of self-injecting capsule could deliver medications at comparable levels to those given via injection, according to a preclinical study.

Insulin 105
article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

Hailed as a breakthrough, Tzield’s approval marks the first of its kind to be introduced since the discovery of insulin, which won the 1923 Nobel Prize in the category of Physiology or Medicine. These therapies work by reprogramming the immune system, preventing it from attacking and eradicating insulin-producing cells in the pancreas.

Insulin 246
article thumbnail

RZ-358 by Rezolute for Hyperinsulinemia: Likelihood of Approval

Pharmaceutical Technology

The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100
article thumbnail

RZ-358 by Rezolute for Hyperinsulinemia: Likelihood of Approval

Pharmaceutical Technology

The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100